Tyler’s Latest Columns

  1. Exciting Areas Of Innovation For Cell Therapies 12/23/2024

    In this segment of the executive roundtable discussion, our panelists express optimism about the promising future of allogeneic cell therapies and discuss other innovations in the field.

  2. Leveraging Directed Evolution To Optimize AAV Vector Design 12/18/2024

    4D Molecular Therapeutics (4DMT) CEO and co-founder, David Kirn, MD, talks about the company’s approach to vector optimization, its product development, and its stage-appropriate buildup of internal GMP manufacturing.

  3. Coya Therapeutics On Developing A Combination Biologic 10/31/2024

    Coya Therapeutic’ executive chairman, Howard Berman, Ph.D., discusses the company's approach to developing a combination biologic and the challenges that multi-targeted therapeutics present.

  4. Inside J&J's Many-Indication mAb 10/30/2024

    Leona Ling, Ph.D.’s relationship with the investigational monoclonal antibody nipocalimab is defined by curiosity, perseverance, and commitment. She discovered the molecule while working for Momenta Pharmaceuticals, and she continues to shepherd it long after J&J's $6.5 billion bid for it in 2020.

  5. Tune Therapeutics On Clinical Readiness, Technology Adoption 10/16/2024

    Heidi Zhang, Ph.D., explains Tune Therapeutics' epigenetic approach to gene therapy and how the company is preparing its lead candidate for the clinic, as well as it's modular approach to automation.

  6. Discovery vs. Hypothesis-Driven Cell Line Development 10/8/2024

    Susan Sharfstein, Ph.D., explains how discovery-driven research can further our understanding of cellular biology and ultimately inform cell line development.

  7. How Platform Technologies Are Shaping The Gene Therapy Landscape 9/30/2024

    Leading experts in gene therapy discuss CMC strategy for platform technologies, product lifecycle management, and the role CDMOs play in moving the space forward.

  8. Gene Therapy CMC Experts On Late-Stage Process Changes 9/27/2024

    At the 2024 Bioprocessing Summit, a panel of CMC experts spoke about the challenges commercializing gene therapies, specifically focusing on considerations for late-stage process changes.

  9. Considerations For AI Use In Biomanufacturing 9/18/2024

    Expert's from this month's Bioprocess Online Live event discuss different use cases for AI and shared their thoughts on the adoption of these technologies. 

  10. Delivering Large Molecules To The CNS, Overcoming The Blood-Brain Barrier 8/29/2024

    Aliada Therapeutics' CSO, John Dunlop, Ph.D., explains the company's blood-brain barrier-crossing delivery platform for large molecules.